Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall st set to open higher as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil rises as US-Iran conflict clouds peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Ultragenyx Pharma (RARE) Misses Q1 EPS by 8c
May 6, 2019 5:03 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($1.82), $0.08 worse than the analyst estimate of ($1.74). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $18.3 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More